Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs M&T Bank Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while M&T Bank Corporation trades at $245.32 (market cap $35.42B). The key difference: M&T Bank Corporation is far larger — about 4.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and M&T Bank Corporation pays a 2.48% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MTB | |
|---|---|---|
Market Cap | $8.04B | $35.42B |
Sector | Health | Financials |
52-Week High | $339.75 | $242.55 |
52-Week Low | $241.71 | $178.63 |
Enterprise Value | $7.85B | — |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
M&T Bank Corporation (MTB) trades at $242.55, up 0.09% today, with a bullish technical signal supported by moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.18 exceeding expectations of $4.02. Revenue grew to $9.63B in 2025, with a net income margin of 29.59%. Recent news highlights Q2 2026 results announcement on July 15, 2026, with expectations of higher net interest income and loan growth.
Outlook remains positive due to strong profitability and dividend stability, but risks include elevated costs and net cash flow volatility. Analyst consensus is mixed with 29% buy ratings, though the price target of $242.72 suggests limited upside from current levels. Investors should weigh solid fundamentals against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
